Sclerotherapy for the mucoceles of the anterior lingual salivary glands with pingyangmycin

Oral Dis. 2014 Jul;20(5):473-6. doi: 10.1111/odi.12155. Epub 2013 Jul 15.

Abstract

Recurrence is very common if the mucoceles of the anterior lingual salivary glands (ALSGs) are treated by surgery due to its anatomic characteristics. Therefore, more effective and less invasive treatment methods are urgently required to be applied instead of surgery. In this study, 40 patients with the mucocele of the ALSGs received the intralesional injections of pingyangmycin, and the median number of injections per patient was 2.075 (range, 1-3). All cases completely recovered with no recurrence after follow-up of more than 16 months. The complications included the local swelling, pain, and ulceration following injection, and all these symptoms resolved 7-10 days after the injection. Taken together, sclerotherapy with pingyangmycin is an effective and safe treatment method for the mucocele of the ALSGs and may be the primary treatment modality.

Keywords: mucocele; pingyangmycin; sclerotherapy; the anterior lingual salivary glands.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bleomycin / analogs & derivatives*
  • Bleomycin / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Mucocele / therapy*
  • Salivary Gland Diseases / therapy*
  • Salivary Glands
  • Sclerotherapy / methods*

Substances

  • Bleomycin
  • bleomycetin